Publications by authors named "M Akao"
Aims: The clinical significance of bundle branch block (BBB) during atrial fibrillation (AF) rhythm in relation to heart failure (HF) events remains to be elucidated. This study aimed to explore the associations between BBB patterns and HF in AF patients.
Methods And Results: We enrolled 2721 AF patients whose baseline electrocardiography during AF rhythm was available from a community-based prospective survey, the Fushimi AF Registry.
Background: Anticoagulation therapy for atrial fibrillation (AF) has undergone major changes following the introduction of direct oral anticoagulants (DOAC) in 2011. However, the transition of anticoagulation therapy for AF patients with severe renal dysfunction remains to be elucidated.
Methods And Results: Follow-up data, including creatinine clearance (CrCl), were available for 3,706 patients in the Fushimi AF Registry.
Article Synopsis
- Atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) often occur together, but there's limited guidance on managing patients with both conditions, prompting the need for this study.
- The study used data from the Fushimi AF Registry in Japan to identify factors predicting serious outcomes (like cardiac death or HF hospitalization) in AF patients with HFpEF, while also testing these predictors in another patient registry.
- Among 755 patients analyzed, critical risk factors for adverse outcomes included being aged 75 or older and having non-cardiovascular diseases like anemia and diabetes; cardiovascular diseases did not show a significant link to these adverse outcomes.
Background: Stroke prevention with direct-acting oral anticoagulant agents in patients with atrial fibrillation confers a risk of bleeding and limits their use. Asundexian, an activated factor XI (XIa) inhibitor, is an oral anticoagulant that may prevent strokes with less bleeding.
Methods: In a phase 3, international, double-blind trial, we randomly assigned high-risk patients with atrial fibrillation in a 1:1 ratio to receive asundexian at a dose of 50 mg once daily or standard-dose apixaban.
Article Synopsis
- The All Nippon Atrial Fibrillation In the Elderly Registry studied over 30,000 elderly Japanese patients with non-valvular atrial fibrillation, focusing on outcomes based on age and type of oral anticoagulants (OACs).
- Results showed that the incidence of stroke, major bleeding, and intracranial hemorrhage increased significantly with age, but plateaued for those aged 90 and over.
- Direct OACs (DOACs) generally resulted in lower event rates compared to warfarin, particularly in patients aged 75-85 years, but had limited effectiveness in reducing major bleeding for patients aged 90 and older, suggesting very-low-dose DOACs might be beneficial for this older